
Kardigan, Inc. (KARD)
Last updated: 2026-10-20 23:04:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Summary
Kardigan, Inc. (KARD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $13.51, with a market capitalization of $1.22B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $12.23 to $27.00. This page covers its latest market performance, valuation, price trends and company information.
Key Market Data
$1.22B | |
$13.06 | |
$27.00 | |
$12.23 | |
$12.94 | |
719.84K | |
518.93K | |
-- | |
$27.00 | |
$12.23 | |
-- | |
-- |
Kardigan, Inc. (KARD) After-Hours Stock Price
Kardigan, Inc. (KARD) is trading at $13.52 in after-hours trading as of 2026-10-20 19:59:53, up 4.44% ($0.58) from the regular-session close of $12.94.
After-hours trading shows how investors are pricing KARD after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Kardigan, Inc. (KARD) 7-Day Stock Price Change
Over the past seven days, Kardigan, Inc. (KARD) moved from $14.67 to $13.51, representing a decline of 7.88% ($1.16).
The stock traded between $12.34 and $15.93 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 602.42 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
KARD 52-Week Price Position
Position in Range: 8.7%
KARD is currently trading at $13.51, placing it 8.7% of the way from its 52-week low of $12.23 to its 52-week high of $27.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
What is Kardigan, Inc. (KARD)?
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Kardigan, Inc. Information
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
How to Buy Kardigan, Inc. (KARD) Stock on MEXC
Eligible investors can buy real shares of Kardigan, Inc. (KARD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Frequently Asked Questions (FAQ)
1.What is Kardigan, Inc. (KARD) stock price today?
2.Is KARD stock going up or down today?
3.What is KARD pre-market price?
4.What is KARD after-hours price?
5.Is KARD stock trading now?
6.Where does KARD sit relative to its 52-week high and low?
7.What sector is Kardigan, Inc. in?
8.What is Kardigan, Inc.'s market capitalization and where is it listed?
9.How is KARD valued in terms of P/E ratio and EPS?
10.Does Kardigan, Inc. pay a dividend?
Explore More US Stocks
Search Stocks
KARD Stock Calculator
Estimate the value between KARD shares and USD.
KARD Shares to USD
1.00 KARD shares = 13.514 USD
Calculations are estimates based on the latest available price and are for reference only.

